首页> 美国卫生研究院文献>Antibiotics >Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library
【2h】

Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library

机译:从临床药物库中鉴定抗致病性大肠杆菌的抗Persister活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Uropathogenic E. coli is a major cause of urinary tract infections (UTIs), but current antibiotics do not always effectively clear the persistent infection. To identify drugs that eliminate uropathogenic E. coli persisters, we screened a clinical drug library consisting of 1524 compounds using high throughput drug exposure assay in 96-well plates. Bacterial survival was assessed by growth on LB plates. We identified 14 drug candidates (tosufloxacin, colistin, sparfloxacin, moxifloxacin and gatifloxacin, enrofloxacin and sarafloxacin, octodrine, clofoctol, dibekacin, cephalosporin C, pazufloxacin, streptomycin and neomycin), which had high anti-persister activity. Among them, tosufloxacin and colistin had the highest anti-persister activity and could completely eradicate E. coli persisters in 3 days in vitro while the current UTI antibiotics failed to do so. Our findings may have implications for the development of a more effective treatment for UTIs.
机译:致病性大肠杆菌是尿路感染(UTI)的主要原因,但是目前的抗生素并不总是能有效清除持续性感染。为了鉴定消除尿路致病性大肠杆菌残留的药物,我们在96孔板上使用高通量药物暴露试验筛选了由1524种化合物组成的临床药物文库。通过在LB平板上的生长评估细菌存活率。我们确定了14种候选药物(托氟沙星,粘菌素,司帕沙星,莫西沙星和加替沙星,恩氟沙星和沙拉沙星,八度碱,氯氟辛醇,地贝卡星,头孢菌素C,帕唑沙星,链霉素和新霉素),它们具有较高的抗perperpers活性。其中,tosufloxacin和粘菌素具有最高的抗持久性杀灭剂活性,并且可以在3天的时间内彻底根除大肠杆菌中的持久性成分,而目前的UTI抗生素则不能。我们的发现可能对开发更有效的尿路感染治疗有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号